Co-Authors
This is a "connection" page, showing publications co-authored by Stephen Tomlinson and Carl Atkinson.
Connection Strength
5.742
-
Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
Score: 0.505
-
Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
Score: 0.441
-
Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol. 2010 Dec 01; 185(11):7007-13.
Score: 0.374
-
Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009 Nov 20; 105(11):1094-101.
Score: 0.349
-
Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol. 2008 Jan 15; 180(2):1231-8.
Score: 0.309
-
Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006 Nov 15; 177(10):7266-74.
Score: 0.285
-
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
Score: 0.262
-
Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
Score: 0.202
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
Score: 0.198
-
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
Score: 0.197
-
A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
Score: 0.192
-
C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol. 2018 09; 11(5):1375-1385.
Score: 0.159
-
Natural immunoglobulin M initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration in mice. Hepatology. 2018 02; 67(2):721-735.
Score: 0.154
-
Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation. 2017 06 19; 14(1):120.
Score: 0.149
-
Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
Score: 0.146
-
Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation. 2015 Dec 30; 12:247.
Score: 0.134
-
Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med. 2014 Aug 25; 211(9):1793-805.
Score: 0.122
-
The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol. 2012 Nov 01; 189(9):4640-7.
Score: 0.107
-
Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol. 2012 Jun 15; 188(12):6309-18.
Score: 0.104
-
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
Score: 0.103
-
Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol. 2012 Feb 01; 188(3):1460-8.
Score: 0.102
-
The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am J Pathol. 2010 Dec; 177(6):3061-70.
Score: 0.094
-
Ketamine-xylazine-acepromazine compared with isoflurane for anesthesia during liver transplantation in rodents. J Am Assoc Lab Anim Sci. 2010 Jan; 49(1):45-51.
Score: 0.089
-
A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009 Oct 01; 183(7):4764-72.
Score: 0.087
-
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009 Aug; 119(8):2304-16.
Score: 0.086
-
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
Score: 0.082
-
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008 Sep 15; 123(6):1357-63.
Score: 0.081
-
Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 2008 Aug 15; 68(16):6734-42.
Score: 0.080
-
A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
Score: 0.077
-
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006 Sep; 169(3):1039-47.
Score: 0.070
-
Complement inhibition alleviates donor brain death-induced liver injury and posttransplant cascade injury by regulating phosphoinositide 3-kinase signaling. Am J Transplant. 2023 Feb 04.
Score: 0.055
-
Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis. Cell Rep. 2022 12 06; 41(10):111742.
Score: 0.054
-
Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Clin Cancer Res. 2020 07 01; 26(13):3481-3490.
Score: 0.044
-
Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
Score: 0.041
-
Memory CD4+ T cells are suppressed by CD8+ regulatory T cells in vitro and in vivo. Am J Transl Res. 2017; 9(1):63-78.
Score: 0.036
-
New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
Score: 0.035
-
A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
Score: 0.034
-
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6061-6.
Score: 0.028
-
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
Score: 0.027
-
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
Score: 0.025
-
Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol. 2011 Oct; 45(4):834-42.
Score: 0.024